What the research examined
Published trials investigated the combination of cagrilintide and semaglutide in adults with type 2 diabetes. A phase 2 trial compared the combination with its components; a phase 3 report compared it with placebo. The publications report weight and glycemic endpoints as well as gastrointestinal adverse events.
How to interpret the findings
The comparator differs between these studies. A combination-versus-placebo result is not a head-to-head comparison with every other compound. Conclusions apply to the studied populations and preparations, with funding and trial design relevant to appraisal.
Research literature
- Phase 2 trial of cagrilintide and semaglutide — PubMed record
Lancet (London, England) · 2023 · PMID 37364590 - Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
The New England journal of medicine · 2025 · PMID 40544432
Links open the indexed paper records. Summaries are based on those records and their available abstracts, not a systematic review or a full-text appraisal of every study.